Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Collaborator: Astellas Pharma Inc

Criteria

Inclusion Criteria:

1. Patients who was included in study ONO-5920-02 and completed the medication for two years

2. Other inclusion criteria as specified in the study protocol

Exclusion Criteria:

1. Patients judged to be unsuitable by safety evaluation as clinical trial subjects by the investigator

2. Patients having secondary osteoporosis or another condition that presents low bone mass

3. Other exclusion criteria as specified in the study protocol